We can’t show the full text here under this license.
Weekly Semaglutide 2.4 mg Injections Are Cost-Effective for Weight Loss in the UK
Updated
Abstract
Semaglutide 2.4 mg subcutaneous injection has an of £14,827/QALY gained compared to diet and exercise alone.
- Semaglutide 2.4 mg s.c. injection resulted in higher total costs and health benefits compared to diet and exercise.
- The cost-effectiveness analysis suggests that semaglutide may be a viable option for weight management in the UK.
- In 90% of cases, semaglutide was cost-effective at a willingness-to-pay threshold of £20,000/QALY.
- For a cohort with type 2 diabetes, the incremental cost-effectiveness ratio was £16,613/QALY gained.
- Sensitivity and scenario analyses support the validity of these findings.
Simplified
Key numbers
£14,827/QALY
Cost-Effectiveness Ratio
for semaglutide 2.4 mg injection vs. diet and exercise.
90%
Cost-Effectiveness Probability
Probability of cost-effectiveness at a willingness-to-pay threshold of £20,000/QALY.
£16,613/QALY
Diabetic Population
for semaglutide in a scenario analysis of the diabetic population.